Soft Matter, Год журнала: 2024, Номер unknown
Опубликована: Дек. 6, 2024
Coacervation emerges as a cutting-edge approach to enhance drug delivery, vaccines, and other therapeutics offer potential improvements in their efficacy. Figure created BioRender. Mirlohi, K. (2024) https://BioRender.com/c81q692.
Язык: Английский
Molecular Cancer, Год журнала: 2025, Номер 24(1)
Опубликована: Янв. 18, 2025
Clinically, multimodal therapies are adopted worldwide for the management of cancer, which continues to be a leading cause death. In recent years, immunotherapy has firmly established itself as new paradigm in cancer care that activates body's immune defense cope with cancer. Immunotherapy resulted significant breakthroughs treatment stubborn tumors, dramatically improving clinical outcome patients. Multiple forms immunotherapy, including checkpoint inhibitors (ICIs), adoptive cell therapy and vaccines, have become widely available. However, effectiveness these immunotherapies is not much satisfying. Many patients do respond disease recurrence appears unavoidable because rapidly evolving resistance. Moreover, can give rise severe off-target immune-related adverse events. Strategies remove hindrances mainly focus on development combinatorial or exploitation novel immunotherapeutic mediations. Nanomaterials carrying anticancer agents target site considered practical approaches treatment. Nanomedicine combined offers possibility potentiate systemic antitumor immunity facilitate selective cytotoxicity against cells an effective safe manner. A myriad nano-enabled currently under investigation. Owing gaps between preclinical studies, nano-immunotherapy faces multiple challenges, biosafety nanomaterials trial design. this review, we provide overview summarize evidence indicating how nanomedicine-based increase efficacy immunotherapies. We also discuss key challenges emerged era nanotechnology-based immunotherapy. Taken together, combination drawing increasing attention, it anticipated will achieve desired success therapy.
Язык: Английский
Процитировано
6
Journal of Controlled Release, Год журнала: 2025, Номер 380, С. 433 - 456
Опубликована: Фев. 11, 2025
Язык: Английский
Процитировано
1
Dentistry Journal, Год журнала: 2025, Номер 13(2), С. 79 - 79
Опубликована: Фев. 13, 2025
Background: Recent advances in mRNA vaccine technology, accelerated by the global COVID-19 pandemic, have generated significant interest their applications beyond infectious diseases. Dentistry has emerged as a promising field for exploring potential of mRNA-based therapies preventing and treating oral Objectives: This narrative review aims to evaluate current status development its preclinical health, focusing on periodontal disease, dental caries, regenerative medicine, implantology, cancer. Methods: The synthesizes findings from studies, including research conducted animal models vitro, assess modulate immune responses promote tissue regeneration cavity. Clinical trials were only mentioned context broader areas implementation such oncology immunotherapy. Results: studies highlight capacity vaccines enhance body's response facilitate repair processes. Despite these results, challenges persist delivering effectively within complex environment. These include stability, delivery mechanisms, modulation responses. Conclusions: While offer promise revolutionizing health care, they face notable limitations concerning safety, efficacy, clinical feasibility. Overcoming obstacles through further is essential unlock full translational ensure safe effective integration into practice.
Язык: Английский
Процитировано
1
Vaccines, Год журнала: 2025, Номер 13(4), С. 337 - 337
Опубликована: Март 21, 2025
Dendritic cells (DCs) act as a bridge between innate and adaptive immunity by presenting antigens to effector immune have shown broad application potential in tumor immunotherapy. However, the clinical translation of DC vaccines encounters significant challenges, such immunosuppressive microenvironment (TME) sub-optimal function vaccine efficacy vivo. In this review, our investigation has uncovered latest developments their cancer immunotherapy, with special emphasis on integration nanotechnology. Several types nanomaterials, including protein cage nanoparticles (NPs), biomimetic NPs, targeted multifunctional been developed enhance antigen presentation ability DCs stimulatory effects T cells. addition, we also summarized synergistic anti-cancer checkpoint inhibitors, chemotherapy, radiotherapy. recent advances nanotechnology made it possible develop novel biomarkers that can capacity stimulate These not only improve accuracy precision design but provide new insights into understanding mechanisms DC-mediated response. Despite challenges pertaining technical complexities individual adaptation production vaccines, personalized immunotherapy based is expected become an important part treatment rapid biotechnology immunology. This review provides perspectives solutions for optimal therapy.
Язык: Английский
Процитировано
1
Journal of Nanobiotechnology, Год журнала: 2024, Номер 22(1)
Опубликована: Ноя. 14, 2024
RNA therapeutics, such as mRNA, siRNA, and CRISPR–Cas9, present exciting avenues for treating diverse diseases. However, their potential is commonly hindered by vulnerability to degradation poor cellular uptake, requiring effective delivery systems. Lipid nanoparticles (LNPs) have emerged a leading choice in vivo delivery, offering protection against degradation, enhanced facilitation of endosomal escape. LNPs encounter numerous challenges targeted vivo, demanding advanced particle engineering, surface functionalization with targeting ligands, profound comprehension the biological milieu which they function. This review explores structural physicochemical characteristics LNPs, in-vivo fate, customization therapeutics. We highlight quality-by-design (QbD) approach beyond liver, focusing on biodistribution, immunogenicity, toxicity. In addition, we explored current strategies associated ensuring repeated-dose efficacy, safety, tissue-specific gene delivery. Furthermore, provide insights into clinical applications various classes diseases finally prospects
Язык: Английский
Процитировано
6
Journal of Drug Delivery Science and Technology, Год журнала: 2025, Номер unknown, С. 106782 - 106782
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
Cancer Immunology Immunotherapy, Год журнала: 2025, Номер 74(4)
Опубликована: Март 12, 2025
Neoantigen vaccines hold great promise in cancer immunotherapy, but the comparative efficacy of different vaccine platforms, particularly context tumor burden (TB), remains insufficiently studied. In this research, we evaluated safety and therapeutic synthetic long peptide mRNA-based vaccines, both designed to target identical neoantigens across Lewis Lung Carcinoma (LLC) burdens. We employed LLC syngeneic mouse model, a widely used preclinical model for aggressive immunosuppressive tumors. Our findings demonstrated that significantly outperformed peptide-based preventing growth mice with low TB. These results underscore potential mRNA as more effective approach treating tumors, contributing valuable insights future development neoantigen-based vaccines.
Язык: Английский
Процитировано
0
Advances in immunology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Genes, Год журнала: 2025, Номер 16(4), С. 376 - 376
Опубликована: Март 26, 2025
The rapid success of messenger (m) RNA vaccines against COVID-19 has pushed the mRNA to forefront drug research. promise mRNA-based therapeutics and in other areas is not new but now emerging stronger. We review basic concepts, key historical aspects, recent research on as a therapeutic molecule fight infectious diseases cancer. also show current patent perspective this field. Altogether, we describe that technology rapidly moving field aiming for bright future.
Язык: Английский
Процитировано
0
Pharmaceutics, Год журнала: 2025, Номер 17(4), С. 441 - 441
Опубликована: Март 29, 2025
Background: Lipid nanoparticles (LNPs) have proven effective in delivering RNA-based modalities. Rapid approval of the COVID-19 vaccines highlights promise LNPs as a delivery platform for nucleic acid-based therapies and vaccines. Nevertheless, improved LNP designs are needed to advance next-generation other gene toward greater clinical success. components formulation excipients play central role biodistribution, immunogenicity, stability. Therefore, it is important understand, identify, assess appropriate lipid developing safe formulation. Herein, this study focused on novel Polysorbate-80 (PS-80)-based LNP. We hypothesized that substituting conventional linear PEG-lipids with PS-80, widely used, biocompatible injectable surfactant featuring branched PEG-like structure, may change biodistribution pattern enhance long-term By leveraging PS-80’s unique structural properties, aimed develop an mRNA-LNP extrahepatic robust freeze/thaw tolerance. Methods: employed stepwise optimization establish both composition buffer yield stable, high-performing PS-80-based SARS-CoV-2 (SC2-PS80 LNP). compared phosphate- versus tris-based buffers stability, examined multiple ratios, evaluated impact incorporating PS-80 (a PEG-lipid) vivo biodistribution. Various analytical assays were performed particle size, encapsulation efficiency, mRNA purity, vitro potency developed humanized mouse model was used measure its immunogenicity over six months storage at −80 °C. Results: Replacing standard 1,2-dimyristoyl-rac-glycero-3-methoxy polyethylene glycol-2000 (PEG-DMG) increased spleen-specific expression mRNA-LNPs after intramuscular injection. Formulating tris-sucrose-salt (TSS) preserved LNP’s physicochemical properties °C, whereas PBS-sucrose (PSS) less protective under frozen conditions. Notably, TSS-based SC2-PS80 elicited potent humoral immunity mice, including high anti-spike IgG titers pseudovirus neutralization, comparable freshly prepared formulations. Conclusions: A formulated TSS confers delivery, strong against following months. These findings offer promising pathway design therapeutics enhanced stability potential.
Язык: Английский
Процитировано
0